Novartis Ag (NVSEF) Non-Current Receivables (2017 - 2025)
Historic Non-Current Receivables for Novartis Ag (NVSEF) over the last 9 years, with Q4 2025 value amounting to $403.0 million.
- Novartis Ag's Non-Current Receivables rose 12513.97% to $403.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $403.0 million, marking a year-over-year increase of 12513.97%. This contributed to the annual value of $403.0 million for FY2025, which is 12513.97% up from last year.
- As of Q4 2025, Novartis Ag's Non-Current Receivables stood at $403.0 million, which was up 12513.97% from $179.0 million recorded in Q4 2024.
- Over the past 5 years, Novartis Ag's Non-Current Receivables peaked at $403.0 million during Q4 2025, and registered a low of $179.0 million during Q4 2024.
- For the 5-year period, Novartis Ag's Non-Current Receivables averaged around $235.4 million, with its median value being $197.0 million (2022).
- Per our database at Business Quant, Novartis Ag's Non-Current Receivables crashed by 1635.51% in 2024 and then skyrocketed by 12513.97% in 2025.
- Quarter analysis of 5 years shows Novartis Ag's Non-Current Receivables stood at $184.0 million in 2021, then grew by 7.07% to $197.0 million in 2022, then rose by 8.63% to $214.0 million in 2023, then decreased by 16.36% to $179.0 million in 2024, then soared by 125.14% to $403.0 million in 2025.
- Its Non-Current Receivables was $403.0 million in Q4 2025, compared to $179.0 million in Q4 2024 and $214.0 million in Q4 2023.